Clinical Trial Update: Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of a new full-length recombinant human Factor VIII for Hemophilia A has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Recombinant Factor VIII (full-length) (Factor VIII recombinant)

Snippet

Sponsor: Bayer | Conditions: Blood Coagulation Disorders, Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2013-11-18